Anti-La antibodies and their use for immunotargeting
AssigneeGEMoaB Monoclonals GmbH
InventorMichael Bachmann
Life of this patent
Estimating the term…
Loading patent…
AssigneeGEMoaB Monoclonals GmbH
InventorMichael Bachmann
Estimating the term…
The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.
Recombinant antibody, comprising
Antibodies which bind specifically an epitope of the human La protein (anti-La antibody) containing regions determining complementarity (complementarity determining regions, CDRs), characterized in that the CDRs of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) comprise the following sequences:
Dependencies are inferred from the claim text.